NOMAD POWER SOLUTIONS, INC.
NMAD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NMAD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NMAD
Nomad Power Solutions, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies, primarily focused on its lead product candidate LB-100, a protein phosphatase 2A inhibitor. The company faces significant financial challenges, including a going concern warning and limited cash runway.
Key risk: Going concern risk
Market Cap
$78.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Nomad Power Solutions, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies, primarily focused on its lead product candidate LB-100, a protein phosphatase 2A inhibitor. The company faces significant financial challenges, including a going concern warning and limited cash runway.
- Clinical-stage biopharmaceutical company focused on cancer therapies, with lead candidate LB-100 targeting protein phosphatase 2A [sec_mda · as of 2025-08-07].
- Cash of $3.25 million as of March 31, 2026, with substantial doubt about ability to continue as a going concern [sec_mda · as of 2026-05-14].
- Shareholders' equity of $9.7 million as of June 30, 2026 [sec].
- No recurring revenues since inception; operations funded through equity sales [sec_mda · as of 2025-11-12].
- Management is considering strategic alternatives to address capital needs [sec_mda · as of 2026-05-14].
What works
- Lead candidate LB-100 has a differentiated mechanism targeting protein phosphatase 2A, which the company believes has broad therapeutic potential for various cancers [sec_mda · as of 2025-08-07].
- Recent equity financings and management changes in 2025 may provide strategic flexibility [sec_mda · as of 2025-11-12].
What to weigh
- Cash of $3.25 million as of March 31, 2026, is insufficient to complete development or commercialization of LB-100 [sec_mda · as of 2026-05-14].
- Independent auditor expressed substantial doubt about going concern for at least 12 months [sec_mda · as of 2026-05-14].
- No recurring revenues and negative operating cash flows since inception [sec_mda · as of 2026-05-14].
- Significant additional financing needed, with uncertainty about ability to raise capital [sec_mda · as of 2026-03-31].
From the filings
Quoted directly from source documents.
Cash position as of March 31, 2026
“of March 31, 2026, the Company had cash of $3,250,650 available to fund its operations.”
SEC MD&A · May 14, 2026
Going concern warning
“management has concluded that there is a substantial doubt regarding the Company's ability to continue as a going concern for a period of at least 12 months beyond the filing of this quarterly report.”
SEC MD&A · May 14, 2026
Lead product candidate LB-100
“The Company's principal product candidate, LB-100, has a mechanism of action that the Company believes differs from t”
SEC MD&A · August 14, 2026
No recurring revenues since inception
“The Company has not generated recurring revenues since inception and has incurred negative operating cash flows as it advances its development programs.”
SEC MD&A · May 14, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Substantial doubt about ability to continue as a going concern for at least 12 months [sec_mda · as of 2026-05-14].
- Insufficient cash runway — Cash of $3.25M as of March 31, 2026, insufficient to complete development or commercialization [sec_mda · as of 2026-05-14].
- No revenue generation — No recurring revenues since inception; negative operating cash flows [sec_mda · as of 2026-05-14].
- Dependence on equity financing — Operations funded solely through equity sales; future capital needs uncertain [sec_mda · as of 2025-11-12].
What to watch
- Ability to raise additional capital to fund operations and clinical trials [sec_mda · as of 2026-05-14].
- Progress of LB-100 clinical trials and any regulatory updates [sec_mda · as of 2026-08-14].
- Outcome of strategic alternatives review [sec_mda · as of 2026-05-14].
- Changes in cash position and going concern status in future filings [sec_mda · as of 2026-05-14].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run NOMAD POWER SOLUTIONS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NOMAD POWER SOLUTIONS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$2.3M
| Holder | Shares | Value |
|---|---|---|
| scotia capital inc. | 283,162 | $869K |
| vanguard capital management llc | 98,958 | $304K |
| renaissance technologies llc | 93,000 | $286K |
| federation des caisses desjardins du quebec | 64,487 | $198K |
| geode capital management, llc | 58,852 | $181K |
| citadel advisors llc | 56,557 | $174K |
| vanguard fiduciary trust co | 35,034 | $108K |
| xtx topco ltd | 23,446 | $72K |
| state street corp | 17,396 | $53K |
| atlas legacy advisors, llc | 13,771 | $42K |
Showing top 10 of 13 institutional holders of NOMAD POWER SOLUTIONS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 0.2%
- Days to cover
- 0.7
- Shares short
- 24,410
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NMAD short interestGovernance
Frequently asked questions
What is the AI investment thesis for NOMAD POWER SOLUTIONS, INC.?
Nomad Power Solutions, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies, primarily focused on its lead product candidate LB-100, a protein phosphatase 2A inhibitor. The company faces significant financial challenges, including a going concern warning and limited cash runway.
Who is the CEO of NOMAD POWER SOLUTIONS, INC.?
Mr. Geordan G. Pursglove is the chief executive officer of NOMAD POWER SOLUTIONS, INC. (NMAD).
Where is NOMAD POWER SOLUTIONS, INC. headquartered?
NOMAD POWER SOLUTIONS, INC. (NMAD) is headquartered in Boca Raton, FL, United States.
What therapeutic areas does NOMAD POWER SOLUTIONS, INC. focus on?
NOMAD POWER SOLUTIONS, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.